BC Week In Review | Dec 21, 2018
Company News

Surface drops after deprioritizing lead product

Surface Oncology Inc. (NASDAQ:SURF) was off $3.52 (48%) to $3.89 on Dec. 19 after the company said late Dec. 18 it will deprioritize Phase I candidate SRF231, one of its two clinical programs. The immunotherapy...
BC Extra | Dec 19, 2018
Company News

Surface drops after deprioritizing lead product

Surface Oncology Inc. (NASDAQ:SURF) was off $3.52 (48%) to $3.89 on Wednesday after the company said late Tuesday it will deprioritize Phase I candidate SRF231, one of its two clinical programs. The immunotherapy company said...
BC Innovations | Oct 18, 2017
Translation in Brief

Neutrophil bias

Researchers from the University of Texas Health Science Center have found that IL-27 promotes an anti-inflammatory phenotype in neutrophils that can treat stroke in mice. But safety issues around the recombinant cytokine have the team...
BC Innovations | Sep 26, 2017
Distillery Therapeutics

Neurology

INDICATION: Stroke Mouse studies suggest IL-27 could help treat intracerebral hemorrhage. In a mouse model of intracerebral hemorrhage, IV injection of IL-27 30 minutes post-hemorrhage, followed by daily subcutaneous injections of IL-27 for six days,...
BC Innovations | Jul 9, 2015
Targets & Mechanisms

Top Translational Targets, 2013-14

Top Translational Targets, 2013-14 The most frequently cited targets from selected disease areas, as published in the Distillery from 2013-14, are shown in the charts below. The top 10 in each disease area were chosen,...
BC Innovations | Jul 17, 2014
Strategy

Partnering in pediatrics

Alexion Pharmaceuticals Inc. is hoping that its research collaboration with Cincinnati Children's Hospital Medical Center will help the biotech build out a rare disease pipeline that currently is dominated by a single molecule- Soliris eculizumab....
BC Innovations | Oct 3, 2013
Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) IL-27 Studies in cell culture and mice suggest IL-27-conditioned dendritic cells (DCs) could help treat MS. In cell culture, DCs treated...
BC Innovations | Oct 3, 2013
Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Viral infection IL-6 signal transducer (IL-6ST; gp130; CD130); IL-27; IL-27 receptor-a (IL27RA) Mouse studies suggest increasing IL-27 signaling through gp130 and IL27RA could help...
BC Innovations | Sep 20, 2012
Distillery Therapeutics

Indication: Ophthalmic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease Uveitis IL-12; IL-27 In vitro and mouse studies suggest a heterodimeric cytokine could help treat uveitis. In mouse T cell proliferation and differentiation assays,...
BC Innovations | Jan 27, 2011
Distillery Therapeutics

Indication: Gastrointestinal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Gastrointestinal disease Colitis IL-27 receptor a (IL27RA) A study in mice suggests that antagonizing IL27RA could help treat colitis. In a mouse model of colitis, transfer...
Items per page:
1 - 10 of 15